ATE482712T1 - Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen - Google Patents

Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen

Info

Publication number
ATE482712T1
ATE482712T1 AT00974007T AT00974007T ATE482712T1 AT E482712 T1 ATE482712 T1 AT E482712T1 AT 00974007 T AT00974007 T AT 00974007T AT 00974007 T AT00974007 T AT 00974007T AT E482712 T1 ATE482712 T1 AT E482712T1
Authority
AT
Austria
Prior art keywords
mesenchymal stem
immune response
transplantations
preventing
stem cell
Prior art date
Application number
AT00974007T
Other languages
German (de)
English (en)
Inventor
Kevin Mcintosh
Joseph Mosca
Elena Klyushenkova
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Application granted granted Critical
Publication of ATE482712T1 publication Critical patent/ATE482712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00974007T 1999-10-26 2000-10-26 Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen ATE482712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/427,333 US6368636B1 (en) 1998-03-18 1999-10-26 Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
PCT/US2000/029815 WO2001032189A1 (en) 1999-10-26 2000-10-26 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation

Publications (1)

Publication Number Publication Date
ATE482712T1 true ATE482712T1 (de) 2010-10-15

Family

ID=23694416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00974007T ATE482712T1 (de) 1999-10-26 2000-10-26 Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen

Country Status (10)

Country Link
US (2) US6368636B1 (https=)
EP (2) EP2269616A3 (https=)
JP (1) JP2004506598A (https=)
AT (1) ATE482712T1 (https=)
AU (1) AU782064B2 (https=)
CA (1) CA2387542C (https=)
DE (1) DE60045034D1 (https=)
ES (1) ES2351203T3 (https=)
PT (1) PT1223956E (https=)
WO (1) WO2001032189A1 (https=)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
DE60141510D1 (de) * 2000-04-11 2010-04-22 Univ Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf-beta zur induktion von t-suppressorzellen
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US20020086005A1 (en) * 2000-11-22 2002-07-04 Choy-Pik Chiu Tolerizing allografts of pluripotent stem cells
EP2305795B1 (en) * 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
EP2316918B1 (en) * 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
ES2432493T3 (es) * 2001-02-14 2013-12-03 Anthrogenesis Corporation Placenta de mamífero post-parto, su uso y células madre de la misma
CA2465672A1 (en) * 2001-09-19 2003-03-27 Henry Ford Health System Cardiac transplantation of stem cells for the treatment of heart failure
WO2003073998A2 (en) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
WO2003101308A1 (en) * 2002-06-04 2003-12-11 Office Of Technology Licensing Stanford University Device and method for rapid aspiration and collection of body tissue from within an enclosed body space
AU2003295444A1 (en) * 2002-11-15 2004-06-15 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20040101959A1 (en) * 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
WO2004047860A2 (de) * 2002-11-28 2004-06-10 Genethor Gmbh Nicht antigen präsentierende, mhc ii exprimierende zellen zur unterdrückung von pathologischen immunreaktionen
ATE482725T1 (de) * 2003-04-01 2010-10-15 Us Dept Of Veteran S Affaires Auf stammzellen, vorläuferzellen oder targetzellen basierende behandlung von multiorganversagen.
GB0321337D0 (en) * 2003-09-11 2003-10-15 Massone Mobile Advertising Sys Method and system for distributing advertisements
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
EP2298864B1 (en) * 2004-03-22 2017-10-11 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
ATE556134T1 (de) * 2004-03-22 2012-05-15 Osiris Therapeutics Inc Mesenchymstammzellen und verwendungendafür
WO2005108559A2 (en) * 2004-04-23 2005-11-17 Bioe, Inc. Multi-lineage progenitor cells
US7622108B2 (en) * 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US20050265980A1 (en) * 2004-05-14 2005-12-01 Becton, Dickinson And Company Cell culture environments for the serum-free expansion of mesenchymal stem cells
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
JP5089389B2 (ja) * 2004-09-10 2012-12-05 コグネート セラピューティクス，インコーポレーテッド 移植における免疫応答の予防および治療のための肝臓間質細胞
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
AU2006205033A1 (en) * 2005-01-11 2006-07-20 Cognate Therapeutics, Inc. Bone marrow stromal cells for immunoprotection of transplanted neural stem cells
JP2008544957A (ja) * 2005-05-10 2008-12-11 ユナイテッド ステイツ オブ アメリカ デパートメント オブ ヴェテランズ アフェアーズ 間充織幹細胞による腎疾患及び多臓器不全の治療法と間充織幹細胞馴化培地
EP3184630B1 (en) * 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US20070082328A1 (en) * 2005-09-27 2007-04-12 Donnie Rudd Rotatable time varying electromagnetic force bioreactor and method of using the same
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
EP1976978A2 (en) 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US11992507B2 (en) 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
CA2646491A1 (en) * 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
KR20090031895A (ko) * 2006-06-09 2009-03-30 안트로제네시스 코포레이션 태반 니치 및 줄기 세포 배양을 위한 이의 용도
US7993918B2 (en) * 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2617428A1 (en) * 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
US7871605B2 (en) 2006-11-03 2011-01-18 Aastrom Bioscience, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
NZ612888A (en) 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
NZ582616A (en) * 2007-06-15 2012-07-27 Garnet Biotherapeutics Inc Treatment of diseases and disorders using self-renewing colony forming cells cultured and expanded in vitro
EP2192908A4 (en) * 2007-07-25 2010-09-01 Bioe Inc DIFFERENTIATION OF PRECURSOR CELLS OF MULTIPLE ABSTRACTS AGAINST CHONDROCYTES
RU2536242C2 (ru) 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
US20100247577A1 (en) * 2007-10-17 2010-09-30 Txcell Tr1 cells, mesenchymal stem cells and uses thereof
US9011840B2 (en) * 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
EP2279246A4 (en) * 2008-05-02 2012-03-28 Massachusetts Inst Technology METHOD AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE
CA2724839A1 (en) * 2008-05-21 2009-11-26 Bioe Llc Differentiation of multi-lineage progenitor cells to pancreatic cells
CA2734237C (en) * 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
CA2734446C (en) 2008-08-22 2017-06-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
RU2015130665A (ru) * 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
DK2375907T3 (da) * 2008-11-21 2019-06-11 Celularity Inc Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
SG178064A1 (en) * 2009-07-21 2012-03-29 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
DK3284818T3 (da) * 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
DK2556145T3 (en) 2010-04-07 2016-11-07 Anthrogenesis Corp Angiogenesis using placental stem cells
EP2555783A1 (en) 2010-04-08 2013-02-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
KR101203954B1 (ko) 2010-04-15 2012-11-22 서울대학교산학협력단 혈관 내피 세포성 중간엽 줄기세포를 포함하는 면역 조절용 조성물
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
US20150283180A1 (en) * 2011-11-04 2015-10-08 The Texas A& M University System Prevention and Treatment of Transplant Rejection with Mesenchymal Stem Cells and/or TSG-6 Protein
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
WO2014130518A1 (en) 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
JP6666240B2 (ja) * 2013-04-12 2020-03-13 フランチェスカ， サベリオ ラ 移植のための臓器の改良
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
EP4218779B1 (en) * 2013-05-22 2026-04-22 National Center Of Neurology And Psychiatry Mesenchymal stem cells and immunogens for use in inducing acquired immunological tolerance
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
RU2644650C2 (ru) 2014-12-01 2018-02-13 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток и способ его получения
WO2016109824A1 (en) * 2014-12-31 2016-07-07 Applied Biologics, Llc Reconstituted amniotic membrane-amniotic fluid combination tissue graft with standardized stem cell component
WO2016170541A1 (en) * 2015-04-21 2016-10-27 Enlivex Therapeutics Ltd. Therapeutic pooled blood apoptotic cell preparations and uses thereof
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11389141B2 (en) 2016-02-01 2022-07-19 RegenMed Systems, Inc. Cannula for tissue disruption
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
RU2708329C2 (ru) 2016-05-31 2019-12-05 Общество с ограниченной ответственностью "Т-Хелпер Клеточные Технологии" Материал стволовых клеток, композиции и способы применения
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN107454845A (zh) * 2017-06-13 2017-12-08 广州赛莱拉干细胞科技股份有限公司 一种防治糖尿病足的干细胞组合物及其应用、干细胞制剂
CN119033819A (zh) 2017-11-22 2024-11-29 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
MX2020011297A (es) 2018-04-25 2020-11-18 Childrens Medical Center Ligandos y substratos de abcb5.
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
PT118103A (pt) 2022-07-13 2024-01-15 Univ Aveiro Biomaterial para imunomodulação, processo de produção e suas aplicações
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
AU2999199A (en) * 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
US6685936B2 (en) * 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
CA2490682A1 (en) 2004-12-16 2006-06-16 Ibm Canada Limited - Ibm Canada Limitee Method and system for advanced downloadings of urls for web navigation
TW200819387A (en) 2006-10-19 2008-05-01 Univ Yuan Ze Micro-reacting device having a micro-channel flow-guiding block

Also Published As

Publication number Publication date
WO2001032189A1 (en) 2001-05-10
AU1244501A (en) 2001-05-14
EP1223956B1 (en) 2010-09-29
CA2387542C (en) 2012-01-24
US20020085996A1 (en) 2002-07-04
DE60045034D1 (de) 2010-11-11
EP1223956A1 (en) 2002-07-24
CA2387542A1 (en) 2001-05-10
US6875430B2 (en) 2005-04-05
WO2001032189A9 (en) 2002-07-04
EP2269616A3 (en) 2012-06-27
US6368636B1 (en) 2002-04-09
PT1223956E (pt) 2010-12-06
ES2351203T3 (es) 2011-02-01
AU782064B2 (en) 2005-06-30
EP2269616A2 (en) 2011-01-05
JP2004506598A (ja) 2004-03-04

Similar Documents

Publication Publication Date Title
ATE482712T1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
ATE319312T1 (de) Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen
ATE316795T1 (de) Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
ES2180653T3 (es) Tratamiento de material biologico antes de la implantacion.
DK0987998T3 (da) Decellulering af væv
DE69837491D1 (de) Menschliche mesenchymale stammzellen aus peripherem blut
ATE265191T1 (de) Herstellungsverfahren von gewebe zur implantation
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
DE69525151D1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
WO2007070301A3 (en) Vascular graft sterilization and decellularization
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DK1150698T3 (da) Anvendelser af vaskulær endotelvækstfaktor i behandlingen af erektil dysfunktion
ATE297217T1 (de) Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
BR0107544A (pt) Composição de promoção de secreção de bile
DE69937892D1 (de) Implantatmaterial
GB2400556B (en) Therapeutic composition for autoimmune conditions
NO20054912D0 (no) Behandling av aspergillus infeksjoner med tymosin alfa 1
DE50004024D1 (de) Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation
SG158124A1 (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
RU2002117852A (ru) Способ лечения больных псориазом в сочетании с хроническим описторхозом
UA6151U (en) Method for treating experimental burns
UA69988A (en) Method for treating complicated choledocholithiasis
ATE419843T1 (de) Methode zur in vitro reduzierung von durch freie radikale induzierte schäden
RU2002122513A (ru) Способ обработки биологических протезов сосудов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties